Annual EBITDA
-$85.06 M
+$8.85 M+9.42%
December 31, 2023
Summary
- As of February 8, 2025, ALGS annual EBITDA is -$85.06 million, with the most recent change of +$8.85 million (+9.42%) on December 31, 2023.
- During the last 3 years, ALGS annual EBITDA has risen by +$9.45 million (+10.00%).
- ALGS annual EBITDA is now -64.38% below its all-time high of -$51.74 million, reached on December 31, 2019.
Performance
ALGS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$19.46 M
+$6.34 M+24.57%
September 30, 2024
Summary
- As of February 8, 2025, ALGS quarterly EBITDA is -$19.46 million, with the most recent change of +$6.34 million (+24.57%) on September 30, 2024.
- Over the past year, ALGS quarterly EBITDA has increased by +$5.76 million (+22.83%).
- ALGS quarterly EBITDA is now -40.25% below its all-time high of -$13.88 million, reached on September 30, 2019.
Performance
ALGS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$91.86 M
-$1.07 M-1.18%
September 30, 2024
Summary
- As of February 8, 2025, ALGS TTM EBITDA is -$91.86 million, with the most recent change of -$1.07 million (-1.18%) on September 30, 2024.
- Over the past year, ALGS TTM EBITDA has dropped by -$6.80 million (-8.00%).
- ALGS TTM EBITDA is now -561.93% below its all-time high of -$13.88 million, reached on September 30, 2019.
Performance
ALGS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ALGS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +9.4% | +22.8% | -8.0% |
| 3 y3 years | +10.0% | +15.7% | -11.5% |
| 5 y5 years | - | +15.7% | -11.5% |
ALGS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +31.7% | -7.9% | +47.3% | -13.0% | +30.5% |
| 5 y | 5-year | -64.4% | +31.7% | -9.4% | +47.3% | -190.1% | +30.5% |
| alltime | all time | -64.4% | +31.7% | -40.3% | +47.3% | -561.9% | +30.5% |
Aligos Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$19.46 M(-24.6%) | -$91.86 M(+1.2%) |
| Jun 2024 | - | -$25.80 M(+20.7%) | -$90.79 M(+8.9%) |
| Mar 2024 | - | -$21.37 M(-15.3%) | -$83.36 M(-2.0%) |
| Dec 2023 | -$85.06 M(-9.4%) | -$25.22 M(+37.2%) | -$85.06 M(+4.2%) |
| Sep 2023 | - | -$18.39 M(+0.1%) | -$81.62 M(+0.4%) |
| Jun 2023 | - | -$18.37 M(-20.4%) | -$81.27 M(-1.4%) |
| Mar 2023 | - | -$23.07 M(+5.9%) | -$82.41 M(-12.2%) |
| Dec 2022 | -$93.91 M | -$21.79 M(+20.7%) | -$93.91 M(-13.9%) |
| Sep 2022 | - | -$18.04 M(-7.5%) | -$109.06 M(-11.4%) |
| Jun 2022 | - | -$19.50 M(-43.6%) | -$123.11 M(-6.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$34.57 M(-6.4%) | -$132.25 M(+6.2%) |
| Dec 2021 | -$124.54 M(+31.8%) | -$36.94 M(+15.1%) | -$124.54 M(+2.9%) |
| Sep 2021 | - | -$32.10 M(+12.1%) | -$121.01 M(+10.4%) |
| Jun 2021 | - | -$28.64 M(+6.6%) | -$109.58 M(+8.4%) |
| Mar 2021 | - | -$26.87 M(-19.6%) | -$101.12 M(+7.0%) |
| Dec 2020 | -$94.51 M(+82.6%) | -$33.40 M(+61.6%) | -$94.51 M(+19.8%) |
| Sep 2020 | - | -$20.67 M(+2.5%) | -$78.90 M(+9.4%) |
| Jun 2020 | - | -$20.17 M(-0.4%) | -$72.11 M(+38.8%) |
| Mar 2020 | - | -$20.26 M(+13.9%) | -$51.93 M(+64.0%) |
| Dec 2019 | -$51.74 M | -$17.79 M(+28.2%) | -$31.67 M(+128.2%) |
| Sep 2019 | - | -$13.88 M | -$13.88 M |
FAQ
- What is Aligos Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Aligos Therapeutics?
- What is Aligos Therapeutics annual EBITDA year-on-year change?
- What is Aligos Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Aligos Therapeutics?
- What is Aligos Therapeutics quarterly EBITDA year-on-year change?
- What is Aligos Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Aligos Therapeutics?
- What is Aligos Therapeutics TTM EBITDA year-on-year change?
What is Aligos Therapeutics annual EBITDA?
The current annual EBITDA of ALGS is -$85.06 M
What is the all time high annual EBITDA for Aligos Therapeutics?
Aligos Therapeutics all-time high annual EBITDA is -$51.74 M
What is Aligos Therapeutics annual EBITDA year-on-year change?
Over the past year, ALGS annual EBITDA has changed by +$8.85 M (+9.42%)
What is Aligos Therapeutics quarterly EBITDA?
The current quarterly EBITDA of ALGS is -$19.46 M
What is the all time high quarterly EBITDA for Aligos Therapeutics?
Aligos Therapeutics all-time high quarterly EBITDA is -$13.88 M
What is Aligos Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ALGS quarterly EBITDA has changed by +$5.76 M (+22.83%)
What is Aligos Therapeutics TTM EBITDA?
The current TTM EBITDA of ALGS is -$91.86 M
What is the all time high TTM EBITDA for Aligos Therapeutics?
Aligos Therapeutics all-time high TTM EBITDA is -$13.88 M
What is Aligos Therapeutics TTM EBITDA year-on-year change?
Over the past year, ALGS TTM EBITDA has changed by -$6.80 M (-8.00%)